Ubs Group Ag Onconova Therapeutics, Inc. Transaction History

Ubs Group Ag

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 13, 2024	BUY	$0.57 - $1.0 $56,039 - $98,315	98,315 Added 37382.13%	98,578 $58,000
Q1 2024 May 13, 2024	SELL	$0.67 - $1.01 $4,956 - $7,471	-7,398 Reduced 96.57%	263 $0
Q4 2023 Feb 09, 2024	BUY	$0.62 - $0.79 $4,710 - $6,002	7,598 Added 12060.32%	7,661 $5,000
Q3 2023 Nov 09, 2023	SELL	$0.71 - $1.15 $3,970 - $6,430	-5,592 Reduced 98.89%	63 $0
Q2 2023 Aug 11, 2023	SELL	$0.67 - $1.42 $5,989 - $12,694	-8,940 Reduced 61.25%	5,655 $6,000
Q1 2023 May 12, 2023	BUY	$0.69 - $1.42 $85 - $176	124 Added 0.86%	14,595 $10,000
Q4 2022 Feb 08, 2023	SELL	$0.63 - $0.97 $5,690 - $8,762	-9,033 Reduced 38.43%	14,471 $9,000
Q3 2022 Nov 10, 2022	BUY	$0.95 - $1.45 $22,043 - $33,645	23,204 Added 7734.67%	23,504 $20,000
Q2 2022 Aug 10, 2022	SELL	$1.04 - $1.9 $3,971 - $7,256	-3,819 Reduced 92.72%	300 $0
Q1 2022 May 16, 2022	BUY	$1.46 - $2.82 $2,463 - $4,757	1,687 Added 69.37%	4,119 $7,000
Q4 2021 Feb 14, 2022	SELL	$2.49 - $3.73 $4,063 - $6,087	-1,632 Reduced 40.16%	2,432 $6,000
Q3 2021 Nov 15, 2021	BUY	$3.81 - $6.76 $510 - $905	134 Added 3.41%	4,064 $16,000
Q2 2021 Aug 13, 2021	BUY	$6.28 - $16.2 $24,680 - $63,666	3,930 New	3,930 $27,000

249K

Ticker ONTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 20,895,600
Market Cap $12.3M
Description
Onconova Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel products to treat cancer. It has two clinical-stage programs, including narazaciclib (ON 123300), a multi-targeted kinase inhibitor that is in Phase I study for solid tumors, as well as hematological malignancies as a single agent...

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

Stay updated on Ubs Group Ag with notifications on news.